Reports

Drug name	NICE TAs	Comments
Trastuzumab infusion	TA257 - Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 TA34 - Guidance on the use of trastuzumab for the treatment of advanced breast cancer TA208 - Trastuzumab for the treatment of HER2-positive metastatic gastric cancer TA107 - Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer	Funding approval should be sought prior to initiation
Trimovate cream	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Moderate potency.
Upadacitinib (Rinvoq®)	TA665 - Upadacitinib for treating severe rheumatoid arthritis TA744 - Upadacitinib for treating moderate rheumatoid arthritis TA829 - Upadacitinib for treating active ankylosing spondylitis TA861 - Upadacitinib for treating active non-radiographic axial spondyloarthritis
Upadacitinib (Rinvoq®)#1.5	TA856 - Upadacitinib for treating moderately to severely active ulcerative colitis TA907 - Deucravacitinib for treating moderate to severe plaque psoriasis
Ustekinumab	TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis	Hospital use only
Ustekinumab (Stelara®)	TA456 - Ustekinumab for moderately to severely active Crohn’s disease after previous treatment TA456 - Ustekinumab for treating moderately to severely active ulcerative colitis
Ustekinumab#13.5	TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis
Varenicline (Champix®)	TA123 - Varenicline for smoking cessation
Vedolizumab	TA342 - Vedolizumab for treating moderately to severely active ulcerative colitis TA352 - Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy	Hospital only - use in line with NICE Off label use - for the treatment of refractory immunotherapy-related colitis
Vemurafenib tablets	TA269 - Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma	National CDF list

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports